Attachment 1 - Purchase Description.pdf

Purchase Description

Name of Item or Project Title:

Compound library of 39 compounds: for the National Center for Advancing Translational Sciences (NCATS) Pharmaceutical Collection (NPC) library update. This is a COVID-19 related activity.

Statement of Need and Purpose:

NCATS is in need of purchasing new drugs approved at 2022 to keep NCATS Pharmaceutical Collection (NPC) library updated to possibly identify new therapeutics for COVID-19

Background Information and Objective:

The NCATS Pharmaceutical Collection (NPC) is a comprehensive, publicly accessible collection of approved and investigational molecular entities for high-throughput screening that provides a valuable resource for both validating new models of disease and better understanding the molecular basis of diseases and interventions. The NPC is composed of a collection of drugs that are approved for human or animal use and drugs that have been in clinical trials. The NPC library is constantly screened at NCATS to identify drugs that can potentially be repurposed for new diseases that are beyond their original indications.

Moreover, the National Center for Advancing Translational Sciences (NCATS) is screening approved drug and mechanistically annotated libraries to identify new therapeutics for COVID-

19. However, the NCATS Pharmaceutical Collection (NPC) drug library is not updated. Thus, the recently approved drugs (2022) shall be acquired to update the NPC library in order to allow NPC to screen the updated library and possibly identify new therapeutics for COVID-19.

Generic Name of Product:

Compound library of 39 compounds

Purchase Description:

The compound library is separated into immediate delivery and later delivery, as described below:

Product_Names CAS Alflutinib 1869057-83-9 Almonertinib 1899921-05-1 Apatinib 1218779-75-9 Carotegrast methyl 401905-67-7 Chiglitazar 743438-45-1 Coblopasvir 1312608-46-0 Dalpiciclib 1637781-04-4 Danoprevir 850876-88-9 Dorzagliatin 1191995-00-2 Ensartinib 1370651-20-9 Flumatinib 895519-90-1

Fluzoparib 1358715-18-0 Fruquintinib 1194506-26-7 Futibatinib 1448169-71-8 Icotinib 610798-31-7 Imrecoxib 395683-14-4 Linperlisib 1702816-75-8 Morinidazole 92478-27-8 Olutasidenib 1887014-12-1 Olverembatinib 1257628-77-5 Omidenepag 1187451-41-7 Orelabrutinib 1655504-04-3 Oteseconazole 1340593-59-0 Pacritinib 937272-79-2 Pamiparib 1446261-44-4 Pimitespib 1260533-36-5 Rezvilutamide 1572045-62-5 Tapinarof/Benvitimod 79338-84-4 Contezolid 1112968-42-9 Allisartan isoproxil 947331-05-7 Darinaparsin 69819-86-9 Ciprofol 1637741-58-2

Ensitrelvir fumaric acid 2757470-18-9 Gefapixant citrate 2310299-91-1

Surufatinib 1308672-74-3

Tegoprazan 942195-55-3

Ansofaxine (Toludesvenlafaxine) 916918-80-4

Valemetostat tosylate 1809336-93-3 Savolitinib (Volitinib) 1313725-88-0

Salient Characteristics:

The salient characteristics of the brand-name or equal compound library include:

• Each compound must be provided at 50mg/100mg quantity;

• Each compound should be provided with a confirmed purity equal or higher than 95%

(≥ 95);

o In case of nonavailability, vendors may provide quotations with lower compound purity. Compounds with less than 90% (<90) purity shall not be considered.

• The compounds shall be delivered no later than 10 weeks;

• Certificate of Analysis and Standard Operating Procedure;

• The compounds must be replenishable. They must be available for resupply or resynthesis if needed for NCATS follow up in the future; and https://scifinder-n.cas.org/navigate/?appId=00386d0f-bd9e-47f4-8024-99dcbc05a571&backKey=63ef3da24157eb0fc4481472&backToPage=1&contentUri=substance%2Fpt%2F1637741582&key=63ef3da24157eb0fc4481472&metricsOrdinal=16&metricsResultType=substance&ordinal=1&resultType=substance&resultView=DETAIL&sortBy=relevance&sortOrder=descending&state=searchDetail.substance&uiContext=365&uiSubContext=551&uriForDetails=substance%2Fpt%2F1637741582 https://scifinder-n.cas.org/navigate/?appId=00386d0f-bd9e-47f4-8024-99dcbc05a571&backKey=63ef3da24157eb0fc4481472&backToPage=1&contentUri=substance%2Fpt%2F2310299911&key=63ef3da24157eb0fc4481472&metricsOrdinal=23&metricsResultType=substance&ordinal=2&resultType=substance&resultView=DETAIL&sortBy=relevance&sortOrder=descending&state=searchDetail.substance&uiContext=365&uiSubContext=551&uriForDetails=substance%2Fpt%2F2310299911 https://scifinder-n.cas.org/navigate/?appId=00386d0f-bd9e-47f4-8024-99dcbc05a571&backKey=63ef3da24157eb0fc4481472&backToPage=1&contentUri=substance%2Fpt%2F1308672743&key=63ef3da24157eb0fc4481472&metricsOrdinal=14&metricsResultType=substance&ordinal=2&resultType=substance&resultView=DETAIL&sortBy=relevance&sortOrder=descending&state=searchDetail.substance&uiContext=365&uiSubContext=551&uriForDetails=substance%2Fpt%2F1308672743 https://scifinder-n.cas.org/navigate/?appId=00386d0f-bd9e-47f4-8024-99dcbc05a571&backKey=63ef3da24157eb0fc4481472&backToPage=1&contentUri=substance%2Fpt%2F942195553&key=63ef3da24157eb0fc4481472&metricsOrdinal=8&metricsResultType=substance&ordinal=2&resultType=substance&resultView=DETAIL&sortBy=relevance&sortOrder=descending&state=searchDetail.substance&uiContext=365&uiSubContext=551&uriForDetails=substance%2Fpt%2F942195553 https://scifinder-n.cas.org/navigate/?appId=00386d0f-bd9e-47f4-8024-99dcbc05a571&backKey=63ef3da24157eb0fc4481472&backToPage=1&contentUri=substance%2Fpt%2F916918804&key=63ef3da24157eb0fc4481472&metricsOrdinal=21&metricsResultType=substance&ordinal=3&resultType=substance&resultView=DETAIL&sortBy=relevance&sortOrder=descending&state=searchDetail.substance&uiContext=365&uiSubContext=551&uriForDetails=substance%2Fpt%2F916918804

• Packing and Shipping as described on this Purchase Description.

Quantity:

1 set as per Purchase Description

Delivery Date:

Delivery is required within ten (10) weeks after receipt of vials supplied by NCATS.

Packing and Shipping:

Vendor shall provide neat compound dispensed into NCATS provided barcoded, tared vials and report the weight to 0.1mg per vial.

The contractor must also provide the following information electronically for each individual compound. This information must be provided via email referencing individual compound vial barcodes:

• Name;

• Catalog Number;

• Amount;

• CAS;

• Vial barcode; and

• Chemical structure or simplified molecular-input line-entry system (SMILES);